CD276-Targeting CAR T-Cell Therapy for Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments for solid tumors, such as chemotherapy, have limited effectiveness, necessitating the development of new therapeutic approaches.
Innovation Solution
A chimeric antigen receptor (CAR) is designed comprising an antigen binding domain specific to CD276, combined with the transmembrane domain of CD8 and intracellular T cell signaling domains of 4-1BB and CD3 zeta, to target and destroy cancer cells expressing CD276.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used to treat solid tumors, then cancer cells can be targeted, but treatment effectiveness is limited and prognosis remains poor
Solution Approach 1:
The patent introduces chimeric antigen receptors (CARs) as intermediary molecules that bridge T-cells and cancer cells. The CARs contain antigen-binding domains that specifically recognize cancer cell surface antigens, while their intracellular domains activate T-cell killing functions, creating a directed and effective anti-tumor response that overcomes the limitations of conventional chemotherapy
2Adaptability or versatility
If conventional cancer treatments are used, then some cancer cells can be targeted, but new therapeutic approaches are needed for solid tumors
Solution Approach 1:
The patent fundamentally changes the therapeutic parameter from non-specific chemotherapy to highly specific CAR-mediated immunotherapy. By modifying the specificity and mechanism of action through engineered antigen receptors, the treatment achieves superior efficacy against solid tumors while maintaining adaptability to different cancer types through targeting of various antigens
Data Source
Figure 1~1D
Figure 2A~2B
Figure 3
AI summary
Chimeric antigen receptors (CARs) that specifically bind to and immunologically recognize CD276 are disclosed. Related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.